Upcoming conferences

Schedule a meeting with our drug development and manufacturing experts at AAPS & CPhI this November

Downloading our Scientific Posters

You are about to download this document, please enter your contact details below to start downloading.

Scientific Posters

An Open-label, Two-period Study Designed to Evaluate and Compare the Mass Balance Recovery and Metabolite Profile of 14C-Deutetrabenazine and 14C-Tetrabenazine in Healthy Male Subjects

Deutetrabenazine (Austedo, Teva) is approved for the treatment of chorea associated with Huntington’s disease (HD) and tardive dyskinesia (TD). Deutetrabenazine is the first deuterated product approved by the FDA and only the second product approved in HD and TD. Deutetrabenazine is a novel VMAT2 inhibitor that is structurally related to tetrabenazine, with two trideuteromethoxy groups at the 9- and 10-positions in tetrabenazine

Would you like to receive further scientific content including case studies, whitepapers and seminar and webinar invitations?
You can find out how we handle your personal information in our privacy policy here.

Ask us a question